CV Therapeutics News
Most Popular CV Therapeutics Story
CV scores $185M royalty deal on Lexiscan
Just a week after gaining regulatory approval for Lexiscan (regadenoson), an injection that increases Read more...
Latest Headlines
- March 16, 2009
- March 12, 2009
- February 27, 2009
- February 23, 2009
- February 20, 2009
- January 28, 2009
- January 27, 2009
- April 16, 2008
- April 11, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
